Fundraise

Onward Therapeutics raises $27.4M Series B for oncology pipeline

What's the deal? Taiwan-based Onward TherapeuticsDealroom has a profile for this one. Try Dealroom → has closed a US$26.1M (about $27.4 million, FX-converted) Series B to advance its clinical-stage oncology programs. Existing backers CDIB Capital Healthcare Ventures and Hong Kong Chlitina International returned, joined by new institutional investors including Beiley BiofundDealroom has a profile for this one. Try Dealroom →, Everbright BiofundDealroom has a profile for this one. Try Dealroom →, Test Rite International, Grand Fortune Venture Capital, Hercules Bioventure PartnersDealroom has a profile for this one. Try Dealroom →, MitoBitTech Venture, and Top Taiwan Venture CapitalDealroom has a profile for this one. Try Dealroom →.

Where the money goes: Proceeds will fund Onward's clinical programs, manufacturing of clinical supplies, and early-stage research. Its pipeline centers on two clinical assets: a tetravalent bispecific antibody, OT-A201, and an off-the-shelf NK-cell therapy, OT-C001, derived from umbilical cord blood.

Why now? This is the company's first capital increase since it moved its global headquarters from Switzerland to Taiwan in October 2025 via a share exchange. It had previously raised US$69.2M. The round was raised in two closings, the second in October 2026.

What's the endgame? The financing builds a local capital base as Onward targets registration on Taiwan's Emerging Stock Board by the end of 2027. "This financing, our first since establishing our global headquarters in Taiwan, allows us to advance our clinical programs while building our R&D presence here," said chairperson and chief executive officer C. Grace Yeh.

What could go wrong? The company reports preliminary clinical activity — tumor responses, disease stabilization, and some complete metabolic responses — but its trials remain ongoing. The results are early, not evidence of clinical success.

The signal: At $27.4 million, the round is a meaningful Taiwan financing for a clinical-stage oncology firm, though modest beside recent regional deals such as Apollomics'Dealroom has a profile for this one. Try Dealroom → $100 million Series B and OriCell's Series B, which topped $120 million. For Onward, the raise matters as much as a market-positioning move as a research one — anchoring its capital, investors, and listing ambitions in Taiwan.

Read more: finance.yahoo.com

Image credit: Generated with Gemini

More top stories